Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The trial will investigate the combination of venetoclax, obinutuzumab and lenalidomide in
patients with treatment-naïve follicular lymphoma. Patients will receive induction treatment
for 0.5 years with venetoclax, obinutuzumab and lenalidomide followed by maintenance
treatment for upto 2 years. Maintenance treatment will be determined by the response at the
end of induction. Following completion of treatment patients will be followed up for 3 years
after the last patient completes induction treatment.